{"filing":{"accession_number":"0001213900-26-080041","cik":"0002075320","ticker":"PLYX","company_name":"Polaryx Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"ea0298434-8k_polaryx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/ea0298434-8k_polaryx.htm"},"events":[{"id":19185,"run_id":17263,"accession_number":"0001213900-26-080041","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Lisa Bollinger, MD, Chief Medical Officer, resigned from her position effective immediately on July 19, 2026. The disclosure centers on the departure of a named executive officer from a key leadership role overseeing clinical and regulatory functions at a therapeutics company. While the company states it does not anticipate impact on clinical timelines, the departure of a CMO is material to investors assessing the company's development capabilities and execution risk.","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":18205,"accession_number":"0001213900-26-080041","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Lisa Bollinger, MD, Chief Medical Officer, resigned from her position effective immediately on July 19, 2026. The disclosure centers on the departure of a named executive officer from a key leadership role overseeing clinical and regulatory functions at a therapeutics company. While the company states it does not anticipate impact on clinical timelines, the departure of a CMO is material to investors assessing the company's development capabilities and execution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:33:37.701810+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18205,"accession_number":"0001213900-26-080041","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Lisa Bollinger, MD, Chief Medical Officer, resigned from her position effective immediately on July 19, 2026. The disclosure centers on the departure of a named executive officer from a key leadership role overseeing clinical and regulatory functions at a therapeutics company. While the company states it does not anticipate impact on clinical timelines, the departure of a CMO is material to investors assessing the company's development capabilities and execution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:33:37.701810+00:00","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-07-21"}]}